

SCIGEN LTD

FURTHER INFORMATION ON THE HEPATITIS B VACCINE DISTRIBUTION AGREEMENT IN CHINA

12 October 2005: In response to market enquiry following the company's announcement on Monday 10 October 2005, SciGen Limited (ASX: SIE) has set out below further information regarding the commercialisation agreement with Hefei Life Science Park Investment & Development Co (HLSPID) for the distribution of SciGen's hepatitis B product, Sci-B-Vac™ in China.

SciGen announces the following additional aspects of its agreement with HLSPID:

- (1) the agreement became effective on 7 October 2005;
- (2) HLSPID is required to order minimum annual quantities of Sci-B-Vac™ over a 7 year period commencing at the start of health registration, anticipated at the end of calendar year 2007. The health registration will be handled by HLSPID;
- (3) the minimum annual quantities over the 7 year period are of equal amounts;
- (4) subject to securing health registration SciGen anticipates generating revenue from the agreement with HLSPID in the first calendar quarter of 2008.

About Sci-B-Vac™:

Sci-B-Vac™ is a third generation recombinant vaccine produced in mammalian cells culture that contains a mixture of three regions of the hepatitis B virus surface proteins that stimulate a faster immune response than other hepatitis B vaccine presently available. Sci-B-Vac™ has been proven safe and effective after testing in more than 3,500 men, women, children and newborn.

About Hefei Life Science Group:

Hefei Life Science Group consist of several wholly owned healthcare companies including Shenzhen Medical Products Co. Ltd (SMPC), which was established in 1982 to import, distribute and market pharmaceuticals and medical equipments in China. Over the years, it secured the distribution of pharmaceutical products from several multi-national companies, including Hoechst, Eli Lilly, Bayer, Ajinomoto and Schering Plough. It has offices all over China and a sales network of over 200 distributors. Its own marketing and sales team covers 500 major hospitals in addition to covering the private sector.

SMPC, a privately held company has significant revenues and include sales of biological products. In order to further invest in, develop and manufacture biopharmaceuticals in China SMP was incorporated into Hefei Life Science Technology Investment & Development (HLSTID) in Hefei City in cooperation with the Hefei Economic and Technological Development Area. It receives strong support from the Hefei government and maintains strong relations with regulatory and health authorities.

"The execution of the Hepatitis B Vaccine agreement with SciGen is one other major commitment in the Biotechnology sector that will significantly contribute to the group expansion and revenues stream" stated the Chairman of HLSTID.

About SciGen™ :

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

Further information:

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800 +61 417 382 391 (mobile) rwilson@bcq.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)